Therapy of Parkinsonian syndrome using L-dopa. Current state and problems
Fischer, P.A.
Der Nervenarzt 45(12): 617-627
1974
ISSN/ISBN: 0028-2804 PMID: 4614096 Document Number: 73392
Document emailed within 1 workday
Related Documents
Indo, T.; Takahashi, A. 1987: Should L-dopa therapy for Parkinson's disease be started early or late? Clinical course of the major tetrad in 122 Parkinsonian patients treated with L-dopa over 14 years Rinsho Shinkeigaku 27(11): 1419-1422Ambrosetto, C.; Martinelli, P. 1971: Clinical considerations on therapy of parkinsonian syndromes with amantadine and L-Dopa Minerva Medica 62(82): 4017-4019
Quattrini, A.; Paggi, A.; Forastieri, L.; Del Pesce, M.; Di Bella, P. 1979: Efficacy and side-effects of long term L-dopa therapy in Parkinsonian syndromes (evaluated by CT scan as well) Rivista di Patologia Nervosa e Mentale 99(5): 289-297
Geissbuhler, F.; Eisenring, J.J.; Friedli, P.; Bartholini, G.; Tissot, R. 1972: Cerebral and peripheral L-dopa uptake in patients with parkinsonian, depressive or manic syndromes administered L-dopa by perfusion combined or not with a decarboxylase inhibitor. Pharmacological effects L'Encephale 61(2): 127-148
Iurasov, V.V.; Kucherianu, V.G.; Kudrin, V.S.; Zhigal'tsev, I.V.; Nikushkin, E.V.; Sandalov, I.G.; Kaplun, A.P.; Shvets, V.I. 1997: The effect of prolonged parenteral administration of liposomes and L-Dopa incorporated into liposomes on metabolism of dopamine and its metabolites in the striatum of mice with experimental parkinsonian syndrome Biulleten' Eksperimental'noi Biologii i Meditsiny 123(2): 150-153
Christiani, K.; Möller, W.D. 1973: Drug therapy of Parkinson's syndrome. Clinical long-term study using L-dopa and the drug conbination L-dopa-decarboxylase inhibitor Münchener Medizinische Wochenschrift 115(16): 711-713
Ciuca, I.; Bulandra, R.; Serbanesco, L.; Ninosu, N. 1972: Comparative value of L-dopa, amantadine, anticholinergics, and their combinations in parkinsonian syndromes Revue Neurologique (Paris) 127(2): 305-308
Bizzarri, B.Mattia.; Tortolini, S.; Rotelli, L.; Botta, G.; Saladino, R. 2015: Current Advances in L-DOPA and DOPA-Peptidomimetics: Chemistry, Applications and Biological Activity Current Medicinal Chemistry 22(36): 4138-4165
Gersten, J.W.; Marshall, C.; Dillon, T.; Schneck, S.A.; Orr, W.; Nelson, C. 1972: External work of walking and functional capacity in Parkinsonian patients treated with L-dopa Archives of Physical Medicine and Rehabilitation 53(12): 547-553
Peppe, A.; Dambrosia, J.M.; Chase, T.N. 1993: Risk factors for motor response complications in L-dopa-treated parkinsonian patients Advances in Neurology 60: 698-702
Ransmayr, G.; Künig, G.; Neubauer, M.; Wagner, M.; Bösch, S.; Kreczy-Kleedorfer, B. 1993: Is the decreasing responsiveness of axial motor symptoms to L-dopa in elderly parkinsonian patients related to age-associated nonparkinsonian pathologies? Advances in Neurology 60: 685-689
Rabadeau Dumas, J.L.; Rondot, P.; Cardon, P. 1977: Development of studies on the treatment of parkinsonian syndromes with levodopa. II. Long-term effects of L-DOPA alone or in combination with a decarboxylase inhibitor Therapie 32(2): 161-172
Fuchs, G. 1997: Parkinson disease--problems in long-term treatment. Dopamine agonists optimize L-dopa therapy Fortschritte der Medizin 115(5): 43-45
Bergonzi, P.; Chiurulla, C.; Gambi, D.; Mennuni, G.; Pinto, F. 1975: L-dopa plus dopa-decarboxylase inhibitor. Sleep organization in Parkinson's syndrome before and after treatment Acta Neurologica Belgica 75(1): 5-10
Routh, J.I.; Bannow, R.E.; Fincham, R.W.; Stoll, J.L. 1971: Excretion of L-dopa and its metabolites in urine of Parkinson's disease patients receiving L-dopa therapy Clinical Chemistry 17(9): 867-871
Gauthier, G.; de Ajuriaguerra, J.; Geissbuhler, F.; Simona, B.; Constantinidis, J.; Yanniotis, G.; Krassoievitch, M.; Eisenring, J.J.; Tissot, R. 1971: Substitutive therapy in Parkinson's syndromes. L-dopa plus peripheral decarboxylase inhibitor or 3-0-methyl dopa? La Presse Medicale 79(3): 91-92
Muenter, M.D.; Tyce, G.M. 1971: L-dopa therapy of Parkinson's disease: plasma L-dopa concentration, therapeutic response, and side effects Mayo Clinic Proceedings 46(4): 231-239
Fischer, P.A.; Schneider, E.; Jacobi, P.; Maxion, H. 1973: Combination therapy of Parkinson's syndrome using L-dopa and a decarboxylase inhibitor Die Medizinische Welt 24(45): 1742-1746
Schmid, P.C. 1977: Current problems in juvenile tuberculosis. 1. The current epidemiological state of tuberculosis Fortschritte der Medizin 95(33): 2009-2012
Kirby, W.M. 1970: Current state of antibiotic therapy Adm; Revista de la Asociacion Dental Mexicana 27(4): 375-378